gbola amusa md cfa head hc research
sale trade et
sale trade et
viral news genet medicin synthet biolog transform cell gt
highlight week januari januari synthet biolog kol call dr jame collin articul
reason synthet biolog though earli could soon potenti transform cell gene therapi feedback
provid chardan genet medicin research report edita medicin buy announc transit
presid ceo katrin bosley effect march note trend manag turnov trend
crispr gene edit space uniqur buy chardan top pick announc fda clear
investig new drug ind applic gene therapi gt huntington diseas
like gt huntington diseas unrat announc
fda clear ind aav-bas gt danon diseas rocket ind aav gt
platform believ rocket could provid one first success aav-bas gt heart condit edita
medicin announc public journal natur medicin preclin data support develop
vivo gene edit candid leber congenit amaurosi may
first vivo crispr-bas gene edit therapi use human feedback microbiom medicin ip
kol call provid chardan genet medicin research report
look forward januari februari januari estimate proqr buy host
 day new york citi includ updat progress sepofarsen formerli name
usher syndrom discuss next therapi enter clinic
weekli price move figur vivo genet medicin aav srna vivo gene edit
upcom chardan genet medicin event contact chardan rsvp
analyst gbola amusa md cfa moder panel pm entitl improv cell therapi via
gener technolog summit
march chardan sponsor gene therapi genom edit summit host orphan
march chardan sponsor arm cell gene therapi investor day new york citi
april chardan sponsor arm meet mediterranean barcelona
gene express intern commiss form address germlin gene edit
januari world econom forum annual meet davo dr dzau presid us
nation academi medicin announc download video entitl gene edit crossroad
intent conven intern commiss would task creat increasingli clear criteria
guidelin topic embryonic/germlin gene edit commiss compos repres
us nation academi medicin royal societi uk commonwealth chines academi
scienc intern organ note dr dzau made distinct gene edit somat
cell versu embryos/germlin cell state somat therapi adult uniform agreement
good thing import advanc treatment diseas question embryonic/
germlin edit difficult one commun continu grappl
committe may abl help creat standard inform govern polici around compel need oversight
protocol requir long-term monitor safeti input ethicist social scientist import
pleas refer import disclosur inform regul analyst certif found page report
establish correct oversight also establish conditions/criteria relat compel need establish safeti
commiss format come chines scientist provid evid world first gene-edit babi
novemb shortli thereaft also follow critic chines scientist dr dzau point
past report includ report nation academi report nuffield council
bioethic although quit good provid need clariti around specif condit may
accept alter germlin dna condit activ absolut prohibit dr
dzau view thing need revisit order decreas subject field intent part
committe provid suffici clariti scientist like dr ration action
believ commiss work directli affect valuat gene edit compani focus somat
buy valid public lead ge asset januari
edita announc public preclin data support develop vivo gene edit
candid leber congenit amaurosi journal natur medicin public
provid addit detail experiment design statist metric
point studi includ guid select appear highli specif data
human mous model suggest could achiev edit beyond target therapeut threshold
non-human primat nhp data point toward similar dose rang albeit notabl standard deviat
cohort edit beyond therapeut threshold could occur dose line use approv ocular
aav-bas gene therapi luxturna analysi immun respons nhp may suggest manag risk profil
upgrad buy januari
upgrad rate buy increas price target
believ current share price repres attract entri point stock believ futur
progress updat dicerna pipelin program could serv valu creation event stock next
month furthermor recent collabor agreement strengthen balanc sheet expand pipelin opportun
provid extern valid compani galxc rnai platform
qure buy ind activ phase i/ii studi januari
uniqur chardan top pick announc fda clear investig new drug ind applic
gt huntington diseas uniqur plan initi phase i/ii studi
pois first-in-human gt huntington diseas
believ differenti approach may advantag versu competit due favor
immunogen profil favor spread/distribut first-mov advantag one-tim treatment lack
safeti issu sometim seen antisens oligonucleotid aso
crispr gene edit ceo departur continu trend exec turnov januari
edita medicin buy announc anticip departur presid ceo katrin bosley effect march
execut departur edita short time preced compani decemb
announc regard plan return cfo andrew hack md phd invest industri also effect
march august announc regard transit gerald cox md phd
understand search underway find non-interim successor ceo cfo posit
note manag turnov crispr gene edit space occur crispr compani
transit preclinical-stag biotech engin focus clinical-stag compani
microbiom medicin ip kol call patent ye januari
chardan host call patent attorney david resnick mark fitzgerald phd nixon peabodi llp
discuss intellectu properti ip landscap microbiom medicin space
takeaway includ despit often naturally-occur patent manipul use make
drug bacteria compon product etc involv engin genetically-modifi
bacteri vector contribut patent protect breadth strength patent protect like depend
way claim written jurisdict like europ provid insight futur landscap
us much like strain-level distinct becom critic therapeut efficaci strain-level distinct
like becom critic success patent current state patent parallel earli monoclon
antibodi suggest initi challeng overcom
page
buy combin aspect genet medicin microbiom medicin addit
gene circuit provid exogen function probiot chassi potenti improv patent protect
compani product metabol diseas like phenylketonuria urea cycl disord
chardan host kol call dr jame collin termeer professor bioengin mit synthet
biolog genet medicin dr macarthur foundat geniu award recipi co-found
number compani includ buy senti bioscienc privat
takeaway includ synthet biolog strong posit soon affect field cell gene therapi
much progress made synthet biolog still earli stage develop like
see first live medicin therapi commerci within next year decis design optim
variou compon gene circuit base indication/ne technic hurdl synthet biolog
remain expect newli emerg technolog rel good regulatori support continu
although challeng ahead big data machin learn pois continu transform field
synthet biolog therapeut commerci opportun synthet biolog space remain
genet medicin news januari januari
unrat list phase i/ii trial mma clinicaltri gov websit januari
buy partner medison pharma privat commerci onpattro israel januari
sclp gb unrat appoint head research head manufactur januari
buy publish preclin data natur medicin januari
qure buy announc fda clearanc ind huntington diseas januari
unrat announc fda clearanc ind danon diseas januari
novemb disclos preclin data first investig gene
therapi program monogen heart failur syndrom danon diseas danon diseas genet syndrom
character heart failur myopathi
ind clear rocket expect phase trial start ucsd assess safeti toler
preliminari efficaci compani also plan publish literatur review danon diseas case conduct
retrospect chart review danon diseas conduct prospect natur histori studi danon diseas
patient enrol begin
crsp buy partner probiogen privat develop vivo deliveri modal januari
neutral appoint robert hesslein gener counsel januari
ortx unrat publish clinic data transf-depend bt natur medicin januari
buy announc ceo katrin bosley step effect march januari
unrat announc fda clinic hold ind develop over-the-counter defici januari
immunochina privat rais mm seri financ januari
unrat appoint adrian woolfson execut vice-president januari
unrat announc price mm offer common stock januari
mit broad institut harvard nih publish human gene edit new platform januari
sight fp buy report mm cash cash equival decemb januari
umrx unrat enter amend loan secur agreement pacif western bank januari
privat plan acquisit antibodi gener unit mab discoveri januari
sjd publish target pathway retinoblastoma oncolyt viru januari
buy partner privat identifi new target rnai intervent liver januari
 california publish mediat super-mendelian inherit mice januari
unrat announc price mm offer common stock januari
page
buy appoint fred cohen board director januari
buy appoint marc kozin anna protopapa board director januari
ion chines academi scienc clone monkey gene-edit macaqu januari
mrk-de unrat grant vertex unrat exclus licens dna-pk inhibitor gene edit januari
harvard univers publish genet modifi hsc/hpc progress ms januari
compani mention report
page
select catalyst genet medicin coverag
provid follow-up data piib dose-confirm studi hemb
axo-lenti-pd report data first patient sunrise-pd phase i/ii trial
present data immun mechan action ovarian cancer
givosiran report top-line data envis piii trial acut hepat porphyria ahp
dcr-hbv initi clinic trial hepat viru pend cta approv
provid initi data phase trial tay-sachs/sandhoff diseas
provid top-line result phase rescu trial lhon
submit ind chronic wound
initi phase i/ii trial autosom recess congenit ichthyosi
report preliminari muscl biopsi result phase i/ii ignit dmd trial dmd
dcr-phxc initi phase ii/iii primari hyperoxaluria pend regulatori feedback
initi patient dose hope-b phase trial hemophilia hemb
file ind rett syndrom
provid program updat phase i/ii valen trial crigler-najjar syndrom
provid continu regulatori updat x-link myotubular myopathi xlmtm
aro-aat initi phase ii/iii studi liver diseas
zolgensma provid clinic data readout strong phase studi sma type
zolgensma anticip regulatori decis sma type
present updat clinic data xlmtm
provid program overview undisclos larg neuromuscular diseas
vy-aadc provid longer term data phase ib trial pd
nsr-rpgr provid follow-up data phase xiriu dose escal studi xlrp
report result piii revers trial result piii rescu trial lhon
file ind inherit amyotroph later sclerosi
file ind cta pomp diseas
complet enrol dose escal phase i/ii trial achm
complet enrol phase iia studi wet
resum enrol phase i/ii studi hofh
dose patient phase trial gangliosidosi
provid earli data cohort phase i/ii pioneer trial n- rp
releas cgmp manufactur phase i/ii studi
initi phase i/ii trial
aav-rpgr prelim dose escal data phase i/ii trial xlrp
optogenet candid collab w/ bionic sight file ind advanc retin diseas
 fc report plan interim readout phase trial rhgg
initi trial malign
complet phase i/ii gem studi dystroph epidermolysi bullosa deb
complet ind-en studi diseas
dose patient phase studi mp
zolgensma anticip approv eu
lumasiran initi illuminate-b -c phase trial
givosiran complet nda applic file applic ahp
provid updat phase i/ii studi hemophilia
report phase i/ii data
provid prelim data phase i/ii patient defici
nsr-rpgr provid prelim data expans cohort phase ii/iii trial xlrp
figur expect zolgensma approv price anticip broad implic vivo gt space
page
select catalyst genet medicin coverag
file ind pomp diseas
submit ema lhon
nsr-rpgr report follow-up data open label dose escal phase xiriu studi
report interim efficaci readout phase oval trial ovarian cancer
report dose escal data pi/ii trial achm/xlrp
xlrp report interim data expans arm phase i/ii trial xlrp
file ind phase ii studi addit propos ophthalm indic
present interim data updat phase i/ii studi mp ii
present interim updat phase studi mp
present interim data cohort steroid prophyl pi/ii studi hofh
file ind batten diseas
initi phase trial dystroph epidermolysi bullosa deb
provid data interim analysi phase i/ii ignit dmd trial dmd
file ind ornithin transcarbamylas over-the-counter defici
provid initi data phase trial gangliosidosi
axo-aav-opmd initi clinic trial opmd phase specifi
report interim phase i/ii data rix nidcr/nih
initi dose phase trial hemophilia
dcr-hbv anticip first interim data clinic trial hbv
initi phase i/ii clinic trial huntington diseas
inclisiran report top-line data orion studi hypercholesterolemia
initi phase iib studi wet
lumasiran present top-line data illuminate-a phase trial
vutrisiran initi helios-b phase studi cardiomyopathi attr amyloidosi
inclisiran file nda hypercholesterolemia
cemdisiran initi phase ii studi iga nephropathi
initi phase i/ii trial
zolgensma complet strong phase trial pre-symptomat sma type
provid updat initi safeti studi hemophilia without inhibitor
 aro-enac file clear cell renal cell carcinoma cystic fibrosi
 fc initi phase ii/iii trial newli diagnos glioblastoma
 fc safeti activ readout phase ib trial met solid tumor
report preliminari data phase i/ii studi batten diseas
submit ind methylmalon acidemia mma
present preclin data new gt program fabri pomp defici
initi phase i/ii trial sjogren syndrom
file ind initi phase i/ii trial al
file ind initi phase i/ii trial wet
initi phase i/ii studi best diseas
 file ind al huntington diseas program
provid follow-up data piib dose-confirm studi hemb
present top-lin data phase i/iia clinic trial wet
initi pivot trial
 fc report final analysi phase trial rhgg
declar develop candid aml
figur alnylam/mdco meira gtx nightstar solid uniqur expect import data read-out
page
select catalyst outsid genet medicin coverag
figur plan file bla aadc defici
report phase i/ii interim data mp ii worldsymposium
provid data updat phase ii trial fabri diseas
begin dose patient investigator-sponsor phase i/ii trial cystinosi
submit ind infantil batten diseas
report interim phase ii data recess dystroph epidermolysi bullosa
initi phase dose escal studi danon diseas
initi phase trial recess dystroph epidermolysi bullosa
 anticip data readout phase trial hd
initi phase ii trial multipl tumor type
begin patient dose phase trial
submit ind relapsed/refractori non-hodgkin lymphoma r/r nhl
aft spear cell report data phase trial hepatocellular carcinoma
initi clinic trial fanconi anemia use process product
submit ind gangliosidosi
initi pivot phase trial rdeb
dtx provid phase i/ii cohort data ornithin transcarbamylas defici
dtx provid pi/ii cohort data glycogen storag diseas type ia gsdia
valoctocogen roxaparvovec valrox provid pi/ii data updat hem
valrox present full piii top-line data hem
valrox submit bla pend fda feedback hemophilia
bmn file ind phenylketonuria pku
provid dystrophin data phase trial dmd
provid interim dystrophin data preclin studi dma
ptc-aadc file bla aromat l-amino acid decarboxylas aadc defici
initi phase ib trial beta-thalassemia
initi phase ii/iii trial dmd
ptc-fa file ind friedreich ataxia fa enter clinic
initi clinic trial charcot-marie-tooth type
lentiglobin initi phase studi sickl cell diseas
initi phase i/ii trial type gaucher diseas
file approv transit clinic trial platform manufactur
report data updat phase i/ii trial hemophilia
initi phase i/ii trial adult phenylketonuria
initi phase i/ii trial leukocyt adhes deficiency-i
rituximab report preliminari phase cohort expans data r/r nhl
sea-bcma report preliminari phase dose escal data r/r mm
micro-dystrophin initi pivot trial duchenn muscular dystrophi
hmaxi-k initi phase ii studi overact bladder
initi phase i/ii trial gangliosidosi
micro-dystrophin initi confirmatori trial commerci materi dmd
tegsedi expect approv brazil hattr amyloidosi
page
corpor report factset chardan note mention stock unrat unless state select public gm compani includ adhera therapeut
benitec biopharma fibrocel buy lysogen oncosec medic oxford biomedica buy vbl neutral
figur select price movement week end januari vivo gm perform driven ivg
page
week-over-week perform vivo genet medicin aav small rna vivo gene edit basketstickerratingccm ptupsideclosechang changemc mm genet medicin cap genet medicin vivo cap genet medicin ex vivo cap gene therapytickerratingccm ptupsideclosechang changemc mm appli genet rna therapytickerratingccm ptupsideclosechang changemc mm arbutu gene editingtickerratingccm ptupsideclosechang changemc mm logicbio pharmaceut
vivo genet medicin monthli market cap progress select compani
corpor report factset chardan note although avx acquir continu includ exhibit reflect valu creation sub-sector
figur aav-bas gene therapyend-monthli market cap select compani januari present
figur small rna therapyend-monthli market cap select compani januari present
figur vivo gene editingend-monthli market cap select compani januari present
page
cap million aav gt sector market cap cap million srna gt sector market cap cap million vivo gene edit sector market cap
aav-bas gene therapi comp meiragtx uniqur chardan top pick
corpor report factset chardan note mention stock unrat unless otherwis state target market cap uncov name model current market cap
refer partner product avexi novarti compani wet hofh mp mp ii phase i/ii trial
figur select public aav-bas gene therapi companiesw prefer buy nite buy buy buy qure buy greater potenti drive upsid aav gt space
page
targettargetccmphas ofpric ccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof genet technolog privat aav-bas genetherapi molecular askbio estev horama myonexu tamid
small rna therapi comp alnylam top pick srna gene therapi offer favor risk-reward dynam
corpor report factset chardan note mention stock unrat unless state target market cap uncov name rgl silenc model current market cap
figur select public small rna therapi companiesw prefer buy greater potenti drive upsid entir small rna space
page
targettargetccmphas ofpric ccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitalnylam privat small rna therapi companiesadvirna silense sirnaom somagen sylentisnot adhera benitec biopharma addit unrat public compani
vivo gene edit comp see greater upsid potenti intellia toolgen
corpor report factset chardan note mention stock unrat unless otherwis state target market cap uncov name model current market cap
figur vivo gene editingw broadli expect out-performance crispr sector higher potenti perform buy toolgen buy
page
targettargetccmphas ofpric ccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitcrispr privat vivogen edit companiesbeam egenesi excis exon feldan poseida precis scienc recombinet
genet medicin therapeut approv posit opinion fda and/or ema
date
date
corpor report fda ema chardan note market author glybera expir due uniqur decis appli renew exclud antisens oligonucleotid figur
figur believ recent increas rate approv posit opinion genet medicin sign sector rapidli emerg
page
genet medicin therapeut receiv fda breakthrough therapi ema prime design
date fda btd
date ema prime
hattr amyloidosi polyneuropathi
corpor report fda ema biopharm insight chardan note ema start grant prime design may fda start grant breakthrough therapi design juli
figur believ disproportion amount btd prime design award genet medicin anoth sign sector rapidli emerg
page
date fda rmat
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur regen medicin advanc therapi design allow compani interact fda earlier clinic test process frequent
prioriti review voucher prv valu prv sold compani compani
date prv sale
ultragenyx undisclos
spark
ultragenyx novarti
biomarin undisclos
price prv
sarepta gilead
unit abbvi
sanofi
knight gilead
biomarin sanofi/regeneron pharmaceut
figur prioriti review voucher prv sold million million
page
date fda rpdd
corpor report fda biopharm insight chardan note list rpdd may incomplet sinc exampl compani disclos regulatori design
figur sinc pediatr diseas design potenti lead prioriti review voucher drug approv hidden sourc valu exist compani
page
date fda ftd
crispr vertex
rp due mutat exon gene
moder sever local scleroderma
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
genet medicin select therapeut receiv btd rmat prime rpdd and/or ftd us eu
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
genet medicin regulatori design btd rmat prime ftd rpdd grant time
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design ema start grant prime design may
fda start grant breakthrough therapi design btd juli pediatr diseas design rpdd rmat design genet medicin began novemb
figur regulatori design btd rmat prime ftd rpdd grant genet medicin consider increas grant
page
designationsyear design grantedgenet medicin regulatori design ytd btdrmatprimeftdrpdd biotechnolog pharmaceut
